Effect of Radioiodine Therapy on Ovarian Reserve in Female Patients With Differentiated Thyroid Cancer

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04396158

Enrollment

Registered

2020-05-20

Start date

2020-06-15

Completion date

2021-12-15

Last updated

2020-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ovarian Insufficiency, Radiation Exposure

Brief summary

Thyroid carcinoma is the most common endocrine malignancy. Surgery is the standard therapeutic approach for patients with differentiated thyroid carcinoma (DTC), followed by radioiodine (RAI) therapy if indicated. For women with DTC, the effects of RAI therapy on gonadal and reproductive function are an important consideration. This study aimed to evaluate the effects of RAI therapy on ovarian function.

Interventions

RADIATIONradioactive iodine

80-200 mCi of radioactive iodine will be given to thyroid cancer patients

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

DIAGNOSTIC

Masking

NONE

Intervention model description

self controlled case series

Eligibility

Sex/Gender

FEMALE

Age

15 Years to 45 Years

Healthy volunteers

Inclusion criteria

* Female patient in childbearing period. * Female patient with differentiated thyroid carcinoma. * Underwent thyroidectomy. * Candidate for radioactive iodine therapy.

Exclusion criteria

* • Male patients. * Postmenopausal female patients. * Female patients with undifferentiated thyroid carcinoma. * Pregnant female patients. * Lactating female patients.

Design outcomes

Primary

Measure	Time frame	Description
Level of anti-Müllerian (AMH) hormone	6 months	Level of anti-Müllerian (AMH) hormone in female patients before and after radioactive iodine therapy.

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026